Arecor Therapeutics plc
AREC.L · LSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | £0 | £0 | £0 | £0 |
| - Cash | £0 | £0 | £0 | £0 |
| + Debt | £0 | £0 | £0 | £0 |
| Enterprise Value | £0 | £0 | £0 | £0 |
| Revenue | £0 | £0 | £0 | £0 |
| % Growth | 10.5% | 90.3% | 107.5% | – |
| Gross Profit | £0 | £0 | £0 | £0 |
| % Margin | 30.5% | 100% | 100% | 100% |
| EBITDA | -£0 | -£0 | -£0 | -£0 |
| % Margin | -200.9% | -183.5% | -418.7% | -541.2% |
| Net Income | -£0 | -£0 | -£0 | -£0 |
| % Margin | -202.6% | -187.1% | -385.4% | -532.7% |
| EPS Diluted | -0.31 | -0.28 | -0.32 | -0.27 |
| % Growth | -10.7% | 12.5% | -18.5% | – |
| Operating Cash Flow | -£0 | -£0 | -£0 | -£0 |
| Capital Expenditures | -£0 | -£0 | -£0 | -£0 |
| Free Cash Flow | -£0 | -£0 | -£0 | -£0 |